Dr. William D. Arnold, M.D.
Physical Medicine & Rehabilitation (PM&R) (Neuromuscular Medicine (Physical Medicine & Rehabilitation) Physician)
- Medicare participating
At a glance
- Medical school
- University of Louisville School of Medicine (2004)
- Years since graduation
- 22
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 13
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2004Medical school: University of Louisville School of Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neuromuscular Medicine (Physical Medicine & Rehabilitation) Physician primary
MO license 2022047326 · OH license 35.093948
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Map: Physical Medicine & Rehabilitation (PM&R) per capita by county →
Where they work
Hospitals
- University of Missouri Health Care Columbia, MO
Medical groups
- The Curators of the University of Missouri (1,131 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 13
- Services billed
- 27
- Patients’ average age
- 70
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Radicava Ors (edaravone) | 22 |
| Riluzole | 19 |
| Ranolazine Er (ranolazine) Other prescribers in Columbia, MO | 15 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 12 payments worth $2,274 in total to this clinician.
| Takeda Pharmaceuticals U.S.A., Inc. | $2,255 |
|---|---|
| Insmed, Inc. | $18.98 |
| Travel and Lodging | $1,924 |
|---|---|
| Food and Beverage | $350 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. Oct 8, 2025 | Travel and Lodging travel to MIAMI, FL · in-kind | $793 |
| Takeda Pharmaceuticals U.S.A., Inc. Oct 4, 2025 | Travel and Lodging travel to MIAMI, FL · in-kind | $480 |
| Takeda Pharmaceuticals U.S.A., Inc. Oct 2, 2025 | Travel and Lodging travel to MIAMI, FL · in-kind | $259 |
| Takeda Pharmaceuticals U.S.A., Inc. Oct 3, 2025 | Travel and Lodging travel to MIAMI, FL · in-kind | $259 |
| Takeda Pharmaceuticals U.S.A., Inc. Oct 2, 2025 | Travel and Lodging travel to MIAMI, FL · in-kind | $133 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $10,840 in research payments for these studies, mostly to the institutions running them.
- A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Takeda Pharmaceuticals U.S.A., Inc. · Recruiting · NCT06798012
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.